1-(1-methylcyclopropyl)butane-1,3-dione

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(1-methylcyclopropyl)butane-1,3-dione
• 化学式: C₈H₁₂O₂
• mdl: MFCD23870441
• 分子量: 140.182
• InChiKey: TVMNZCFYXCOIGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-甲基环丙烷-1-羧酸 在 草酰氯 、 N,N-二甲基甲酰胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 1-(1-methylcyclopropyl)butane-1,3-dione
  参考文献：
  名称：

  [EN] SUBSTITUTED 5-METHYL-[1, 2, 4] TRIAZOLO [1,5-A) PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS
  [FR] COMPOSÉS 5-MÉTHYL-[1, 2, 4]-TRIAZOLO-[1,5-A)-PYRIMIDIN-2-AMINES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE PDE2

  摘要：

  该发明提供了化学实体的化学式(I): (I)，其中R1、R2、R3和R4具有本文所述的任何值，以及包含这种化学实体的组合物；制备它们的方法；以及它们在广泛的方法中的应用，包括代谢和反应动力学研究；检测和成像技术；放射性治疗；调节和治疗由PDE2活性介导的疾病；治疗神经系统疾病、中枢神经系统疾病、痴呆、神经退行性疾病和创伤相关的功能丧失；治疗中风，包括中风康复期间的认知和运动缺陷；促进神经保护和神经恢复；增强认知和运动训练的效率；以及治疗外周疾病，包括血液学、心血管学、胃肠学和皮肤病。

  公开号：

  WO2016073424A1

文献信息

• Depsipeptides and Their Therapeutic Use
  申请人：Shuttleworth Stephen Joseph

  公开号：US20110112090A1

  公开（公告）日：2011-05-12

  A Compound of structure (IX) or (X) or a pharmaceutically acceptable salt thereof, wherein: X is —C(═O)N(R 10 )— or —CH(OPr 3 )—; R 7 , R 9 and R 10 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid; Pr 1 and Pr 2 are the same or different and represent hydrogen or a thiol protecting group; Pr 3 is hydrogen or an alcohol protecting group; R 1 , R 2 , R 5 and R 6 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid, or R 1 and R 2 and/or R 5 and R 6 , taken together with the carbon atom to which they are attached, form a spirocyclic moiety, with the proviso that: each of R 1 and R 2 is not hydrogen, or each of R 5 and R 6 is not hydrogen.

  一种结构化合物（IX）或（X）或其药学上可接受的盐，其中：X为—C(═O)N(R10)—或—CH(OPr3)—；R7、R9和R10相同或不同，代表氢或来自天然或非天然氨基酸的氨基酸侧链基团；Pr1和Pr2相同或不同，代表氢或巯基保护基团；Pr3为氢或醇保护基团；R1、R2、R5和R6相同或不同，代表氢或来自天然或非天然氨基酸的氨基酸侧链基团，或R1和R2和/或R5和R6，与它们连接的碳原子一起形成螺环基团，条件是：R1和R2中的每一个都不是氢，或R5和R6中的每一个都不是氢。
• Chemical Compounds
  申请人：Rees David Daryl

  公开号：US20080045591A1

  公开（公告）日：2008-02-21

  Compounds of general formula I: wherein: R 1 and R 2 are, independently of each other, selected from hydrogen, optionally substituted C 1-10 alkyl, optionally substituted —CO—(C 1-10 alkyl), optionally substituted C 3-10 cycloalkyl, optionally substituted —CO—(C 3-10 cycloalkyl), optionally substituted C 2-10 alkenyl, optionally substituted —CO—(C 2-10 alkenyl), optionally substituted aryl, and optionally substituted —CO-aryl, or R 1 and R 2 together represent an optionally substituted saturated or unsaturated C 1-10 alkylidene group, or an optionally substituted saturated or unsaturated C 3-10 cycloalkylidene group, or R 1 and R 2 together with the carbon atom to which they are attached represent an optionally substituted saturated or unsaturated organic ring containing 3, 4, 5, 6, 7 or 8 ring carbon atoms and optionally 1, 2 or 3 ring heteroatoms selected from O, N and S; R 3 , which may be the same as, or different from, either of R 1 and R 2 , is selected from optionally substituted C 1-10 alkyl, optionally substituted C 3-10 cycloalkyl, optionally substituted C 2-10 alkenyl, and optionally substituted aryl; R 4 , R 5 and R 6 are, independently of each other, selected from hydrogen, optionally substituted C 1-10 alkyl, OH, optionally substituted C 1-10 alkoxy, halo, optionally substituted aryloxy, optionally substituted (C 1-10 alkyl)-S(O) n — where n=0, 1 or 2, optionally substituted aryl-S(O) n — where n=0, 1 or 2, or R 4 is hydrogen and R 5 and R 6 together represent an optionally substituted saturated or unsaturated organic chain containing 1, 2, 3, 4, 5, 6 or 7 chain carbon atoms and optionally 1, 2 or 3 chain heteroatoms selected from O, N and S, provided that the chain is at least 3 atoms long; with the proviso that, when R 1 ═R 2 =hydrogen, then any optionally substituted C 1-10 alkyl or optionally substituted C 2-10 alkenyl for R 3 must have a branch point at one or more of the α and β positions counted from the carbonyl group (or tautomeric form thereof) to which R 3 is attached; or a physiologically acceptable salt, complex or prodrug thereof; are disclosed per se and for use in the treatment or prophylaxis of hypersensitivity, smooth muscle disorders, spasmodic conditions, allergic conditions, inflammatory conditions and/or pain.

  通式I的化合物： 其中： R1和R2独立地选自氢，可选取代的C1-10烷基，可选取代的—CO—（C1-10烷基），可选取代的C3-10环烷基，可选取代的—CO—（C3-10环烷基），可选取代的C2-10烯基，可选取代的—CO—（C2-10烯基），可选取代的芳基和可选取代的—CO-芳基，或者R1和R2一起代表一个可选取代的饱和或不饱和的C1-10烷基亚基，或一个可选取代的饱和或不饱和的C3-10环烷基亚基，或者R1和R2与它们连接的碳原子一起代表一个可选取代的含有3、4、5、6、7或8个环碳原子和可选取代的1、2或3个从O、N和S中选取的环杂原子的饱和或不饱和的有机环； R3可以与R1和R2中的任何一个相同或不同，选自可选取代的C1-10烷基，可选取代的C3-10环烷基，可选取代的C2-10烯基和可选取代的芳基； R4、R5和R6独立地选自氢，可选取代的C1-10烷基，OH，可选取代的C1-10烷氧基，卤素，可选取代的芳氧基，可选取代的（C1-10烷基）-S（O）n-，其中n=0、1或2，可选取代的芳基-S（O）n-，其中n=0、1或2，或者R4为氢，R5和R6一起代表一个可选取代的含有1、2、3、4、5、6或7个链碳原子和可选取代的1、2或3个链杂原子的饱和或不饱和的有机链，前提是该链至少由3个原子组成； 但是，当R1=R2=氢时，R3必须选取一个可选取代的C1-10烷基或可选取代的C2-10烯基，其中至少有一个分支点位于从R3所连接的羰基（或其互变异构体）计算的α和β位置之一；或其生理上可接受的盐、络合物或前药，本发明公开了其本身和用于治疗或预防过敏、平滑肌障碍、痉挛性疾病、过敏性疾病、炎症性疾病和/或疼痛。
• Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
  申请人：DART NEUROSCIENCE (CAYMAN) LTD.

  公开号：US10239882B2

  公开（公告）日：2019-03-26

  The invention provides a chemical entity of Formula (I): (I), wherein R1, R2, R3, and R4, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.

  本发明提供了式(I)的化学实体：(I)，其中 R1、R2、R3 和 R4 具有本文所述的任一值，以及包含这种化学实体的组合物；制造它们的方法；以及它们在多种方法中的用途，包括代谢和反应动力学研究；检测和成像技术；放射性治疗；调节和治疗由 PDE2 活性介导的疾病；治疗神经系统疾病、中枢神经系统疾病、痴呆症、神经退行性疾病和创伤依赖性功能丧失；治疗中风，包括中风康复期间的认知和运动障碍；促进神经保护和神经恢复；提高认知和运动训练的效率；以及治疗外周疾病，包括血液病、心血管病、肠胃病和皮肤病。
• SUBSTITUTED 5-METHYL-[1, 2, 4]TRIAZOLO [1,5-A) PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS
  申请人：Dart NeuroScience (Cayman) Ltd.

  公开号：EP3215508A1

  公开（公告）日：2017-09-13
• SUBSTITUTED 5-METHYL-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2-AMINE COMPOUNDS AS PDE2 INHIBITORS
  申请人：DART NEUROSCIENCE (CAYMAN) LTD.

  公开号：US20180282338A1

  公开（公告）日：2018-10-04

  The invention provides a chemical entity of Formula (I): (I), wherein R 1 , R 2 , R 3 , and R 4 , have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, and dermatological disorders.